B-Cell Maturation Antigen (BCMA) Targeted Therapies Market Report 2026

The b-cell maturation antigen (bcma) targeted therapies market size has grown exponentially in recent years. It will grow from $15.09 billion in 2025 to $18.75 billion in 2026 at a compound annual growth rate (CAGR) of 24.3%. The growth in the historic period can be attributed to improved understanding of bcma biology, increasing multiple myeloma prevalence, early clinical success of bcma-targeted therapies, expansion of hematology oncology centers, rising investment in immuno-oncology research.

The b-cell maturation antigen (bcma) targeted therapies market size is expected to see exponential growth in the next few years. It will grow to $44.29 billion in 2030 at a compound annual growth rate (CAGR) of 24%. The growth in the forecast period can be attributed to increasing approvals of next-generation bcma therapies, rising demand for off-the-shelf immunotherapies, expansion of combination treatment strategies, growing focus on durable remission outcomes, increasing use of ai-driven patient stratification. Major trends in the forecast period include increasing adoption of car-t cell therapies, rising development of bispecific antibody platforms, growing use of bcma-targeted adcs, expansion of personalized immunotherapy regimens, enhanced focus on relapsed and refractory myeloma care.

The increasing incidence of multiple myeloma is expected to drive the growth of the B-cell maturation antigen (BCMA) targeted therapies market in the coming years. Multiple myeloma is a cancer that primarily affects plasma cells, which are an essential part of the immune system responsible for producing antibodies. The rising occurrence of multiple myeloma is linked to various factors, including an aging global population, enhanced diagnostic capabilities, and differences in healthcare access. B-cell maturation antigen (BCMA) targeted therapies play a vital role in treating multiple myeloma by specifically targeting and eliminating malignant plasma cells that express BCMA, providing a promising approach for more effective and targeted treatment. For example, in August 2024, according to the American Cancer Society, a US-based professional organization, around 35,780 new cases of multiple myeloma were diagnosed in the United States, including 19,520 cases in men and 16,260 cases in women. Furthermore, approximately 12,540 deaths are expected, with 7,020 in men and 5,520 in women. Consequently, the rising incidence of multiple myeloma is fueling growth in the B-cell maturation antigen (BCMA) targeted therapies market.

Major companies in the B-cell maturation antigen (BCMA) targeted therapies market are concentrating on developing innovative treatments such as CAR-T cell therapy to improve the efficacy and precision of targeting cancer cells. CAR-T cell therapy is a form of immunotherapy that involves modifying a patient’s T cells to express chimeric antigen receptors (CARs) to identify and eliminate cancer cells. For example, in April 2024, Johnson & Johnson, a US-based pharmaceutical company, received U.S. Food and Drug Administration (FDA) approval for CARVYKTI. CARVYKTI (ciltacabtagene autoleucel) is a BCMA-targeted, genetically engineered autologous T-cell immunotherapy for treating adult patients with relapsed or refractory multiple myeloma who have received at least one prior line of therapy and are refractory to lenalidomide.

In February 2024, AstraZeneca Plc, a UK-based pharmaceutical company, acquired Gracell Biotechnologies Inc. for approximately $1.2 billion. Through this acquisition, AstraZeneca aims to strengthen its cell therapy portfolio by incorporating Gracell's FasTCAR-enabled GC012F therapy, which targets cancer and autoimmune diseases, to address significant unmet medical needs. Gracell Biotechnologies Inc. is a China-based biotechnology company focused on developing B-cell maturation antigen (BCMA) therapies for multiple myeloma and B-cell malignancies.

Major companies operating in the b-cell maturation antigen (bcma) targeted therapies market are Bristol Myers Squibb Company, Novartis, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Amgen Inc, Regeneron Pharmaceuticals, BeiGene, Arcellx Inc, Poseida Therapeutics, Legend Biotech Corporation, Cartesian Therapeutics, Sutro Biopharma Inc, CARsgen Therapeutics, Precision BioSciences, Eureka Therapeutics Inc, Cellectis, Allogene Therapeutics, Affimed, Bluebird Bio Inc, Roche, Ichnos Sciences.

North America was the largest region in the B-cell maturation antigen (BCMA) targeted therapies market in 2025. The regions covered in the b-cell maturation antigen (bcma) targeted therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the b-cell maturation antigen (bcma) targeted therapies market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the BCMA targeted therapies market by increasing costs of imported biologics manufacturing equipment, cell processing systems, reagents, and specialized pharmaceutical ingredients. North America and Europe are most affected due to complex cross-border supply chains for advanced biologics, while Asia-Pacific faces higher costs for clinical-scale manufacturing inputs. These tariffs are increasing production expenses and therapy pricing pressures. At the same time, they are encouraging domestic biologics manufacturing, localized cell therapy infrastructure, and regional investments in advanced biopharmaceutical production capabilities.

The b-cell maturation antigen (bcma) targeted therapies market research report is one of a series of new reports that provides b-cell maturation antigen (bcma) targeted therapies market statistics, including b-cell maturation antigen (bcma) targeted therapies industry global market size, regional shares, competitors with a b-cell maturation antigen (bcma) targeted therapies market share, detailed b-cell maturation antigen (bcma) targeted therapies market segments, market trends and opportunities, and any further data you may need to thrive in the b-cell maturation antigen (bcma) targeted therapies industry. This b-cell maturation antigen (bcma) targeted therapies market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

B-cell maturation antigen (BCMA) targeted therapies are a group of treatments designed to specifically focus on BCMA, a protein found on the surface of mature B-cells and plasma cells. BCMA belongs to the tumor necrosis factor (TNF) receptor superfamily and plays an essential role in B-cell development, survival, and differentiation into plasma cells. BCMA-targeted therapies mark a notable advancement in the management of multiple myeloma, providing effective options for patients with relapsed or refractory disease.

The main types of products for B-cell maturation antigen (BCMA) targeted therapies include antibody-drug conjugates (ADCs), chimeric antigen receptor T (CAR-T) cell therapy, and bispecific antibodies. Antibody-drug conjugates (ADCs) are targeted treatments that combine a cancer-specific antibody with a cytotoxic drug, allowing for precise elimination of cancer cells while reducing harm to healthy tissue. The primary indications include acute lymphoblastic leukemia and multiple myeloma, and these therapies are utilized by various end users such as hospitals, specialty clinics, and home care settings.

The B-cell maturation antigen (BCMA) targeted therapies market consists of revenues earned by entities by providing services such as research and development services, clinical trials management, manufacturing and production services, regulatory consulting and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The B-cell maturation antigen (BCMA) targeted therapies market also includes sales of antibody-drug conjugates (ADCs), BCMA-targeted immunotherapies, and gene therapies. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.